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Purpose: To investigate the effect of ultra low molecular 
weight heparin (ULMWH) on glutamate induced apoptosis 
in rat cortical cells and to explore the possible mechanisms. 
Materials and Methods: Cell viability was measured using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
assay. Apoptosis was first analyzed with Hoechst 33258 and 
then confirmed by DNA fragmentation. The concentration of 
free intracellular calcium ([Ca
2+]i) was determined with 
fura-2/AM fluorometry. The expression of Bcl-2 family 
protein and caspase-3 were evaluated with Western blot. 
Results: Typical apoptotic morphological change in rat 
cortical cells treated with 100 μmol/L glutamate for 24 h 
was detected by Hoechst 33258 staining, which was then 
confirmed by the DNA ladder of agarose gel electrophoresis. 
The apoptotic rate of the glutamate treated cells was up to 
33.21%, and 24 h of treatment with glutamate increased 
[Ca
2+]i, down-regulated Bcl-2 expression, up-regulated Bax 
expression, and increased caspase-3 activation in rat cortical 
cells. Our research demonstrated that ULMWH pretreatment 
can prevent the glutamate- induced apoptosis, attenuate the 
increase of [Ca
2+]i not only in medium containing Ca
2+ but 
also in Ca
2+-free medium, up-regulate the expression of 
Bcl-2, down-regulate the expression of Bax, and decrease 
caspase-3 activation. Conclusion: ULMWH has neuroprotec-
tive capacity to antagonize glutamate-induced apoptosis in 
cortical cells, through decrease of Ca
2+ release and modula-
tion of apoptotic processes.
Key Words: Ultra low molecular weight heparin, glutamate, 
apoptosis, Ca
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INTRODUCTION
Heparins (UFH)-like compounds, including low 
molecular weight heparin (LMWH), have been 
shown to have an important impact on the aggre-
gation, degradation, and toxicity of β-amyloid 
peptide (Aβ),
1,2 suggesting their potential roles in 
the treatment of Alzheimer’s disease (AD). Since 
the compounds with high molecular weight 
(MW) can not penetrate the blood brain barrier 
(BBB), their therapeutic use is greatly diminished. 
Therefore, the compound with low MW may 
have more therapeutic value in the treatment of 
AD than the larger molecular substances. A 
LMWH of MW 4500 can bring about nuropro-
tection when administered both externally and 
intraneuronally, but UFH of M.W. 12,000 works 
only when injected into the cells,
3 suggesting that 
the larger UFH molecule cannot pass through the 
cell membrane, while the smaller LMWH 
molecule does indeed enter the cell. Ultra low 
molecular weight heparin (ULMWH) is currently 
under development, and it exhibits a much 
smaller average MW and a much narrower 
distribution. It has been reported that ULMWH 
has a great ability to penetrate the BBB,
4 
indicating that it may have a much greater ability 
to modulate the functionality of the central 
nervous system. Our laboratory recently showed 
that ULMWH can protect brain from the ischemic 
injury in rats in vivo and its mechanism may be 
partly attributed to scavenging free radicals by 
antioxidant enzymes and modulating Ca
2+ 
homeostasis.
5 In order to deeply and extensively 
explore its neuroprotective effects, we performed ULMWH on Glutamate-Induced Apoptosis 487
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lots of in vitro experiments and found that 
ULMWH could attenuate glutamate-induced 
cortical cell death (data not shown). As an exten-
sion of the research, we investigated the neuro-
protective effects of ULMWH in the current study. 
The effects of ULMWH on glutamate- induced 
neurotoxicity, intracellular Ca
2+ levels ([Ca
2+]i), Bax/ 
Bcl-2 expression and caspase-3 protease activation 
were investigated. Three basic questions were 
addressed: (1) whether ULMWH has protective 
effects on glutamate-induced neurotoxicity; (2) 
whether changes in ([Ca
2+]i are induced by ULMWH 
or glutamate correlated with this protective func-
tion; (3) whether the protective effects of ULMWH 
are due to apoptosis/the apoptotic process. 
MATERIALS AND METHODS
Materials
Ultra low molecular weight heparin (ULMWH) 
(mean MW = 2200) was sodium salt obtained from 
Institute of Biochemical and Biotechnological 
Drugs, School of Pharmacy, Shandong University. 
Pregnant Wistar rats were provided by Experi-
mental Animal Center of Shandong University. 
Glutamate, Dulbecco's modified Eagle's medium 
(DMEM), fetal bovine serum (FBS), poly-L-lysine, 
trypsin, B27 supplement, and neurobasal medium 
were all provided by Gibco (Logan, UT, USA). 
Hoechst 33258 was purchased from Sigma 
Chemical Company (St Louis, MO, USA). Cleaved 
caspase-3 was from Cell signaling (Beverly, MA, 
USA), and Bcl-2, Bax, and β-actin from Neomarker 
(Fremont, CA, USA). ECL was obtained from 
Amersham Pharmacia (Buckinghamshire, UK), 
Fura-2 AM was from Biotium (Hayward, CA, USA), 
and DNA extraction kit from Promega (Madison, 
WI, USA). All other chemicals used were of the 
highest grade available.
Cell cultures
Rat cortical cells were isolated from brain 
according to the procedures with slight modifica-
tions as described previously.
6 Briefly, the cerebral 
cortice from E18 (embryonic day)-E19 Wistar rat 
was dissected under sterile conditions, triturated 
through a fire-polished pipettes, digested at 37℃ 
with 0.125% trypsin in d-Hank’s solution for 15 
min, and centrifuged at 310 g for 10 min. The 
resulting pellets were resuspended in Dulbecco’s 
modified Eagle’s medium (DMEM) and an aliquot 
was stained with 4% trypan blue for live cells 
count using a hemocytometer. The suspension was 
appropriately diluted with neurobasal medium 
containing 2% B27 supplement and 1% penicillin/ 
streptomycin, and seeded in poly-L-lysine-coated 
24, 96-well culture plates (Corning, Acton, MA, 
USA) or 75 cm
2 Falcon Primaria flasks (Becton 
Dickinson, NJ, USA) at a density of (1 - 2) × 10
6 
cells/mL in a humidified incubator with 5% CO2 
overnight at 37℃, then the culture medium was 
completely replaced with fresh medium. During the 
subsequent 7 - 8 days culture, the cells were refed 
every other day by replacing only one third of the 
medium with fresh one. Few glial cells can be 
detected in the cortical cultures by using anti-rat 
neuronal specific enolase (NSE) and anti-glial 
fibrillary acidic protein (GFAP, unpublished 
observations).
Cell treatments
After cultured for 7 or 8 days, cortical cells in 
fresh medium were divided into four groups for 
different treatments: control cells (not treated with 
glutamate or ULMWH), 24 h treatment with 100 
μmol/L glutamate, 24 h treatment with 1 mg/L 
ULMWH, and 24 h treatment with 1 mg/L ULMWH 
followed by treatment with 100 μmol/L glutamate 
24 h later. ULMWH was first dissolved in culture 
medium to give appropriated concentrations, and 
glutamate was diluted in phosphate buffered 
saline (PBS, pH 7.4).
Cell viability assay 
The cultures were assessed for viability by MTT 
assay.
7 In brief, 100 μL of MTT (0.5 mg/mL in 
PBS) was added to each well. After 4 - 6 h in-
cubation at 37℃, 100 μL of DMSO was added and 
mixed well. Plates were agitated on a microtiter 
plate shaker to ensure a homogeneous solution, 
and optical densities (OD) at 570 nm were deter-
mined by using an automated spectrophotometric 
plate reader (Bio-Tek ELX808, Winooski, VT, USA). Tian-gui Yu, et al. 488
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Staining of chromatin using Hoechst 33258
Hoechst 33258 staining was used to reveal 
nuclear morphological changes in cultured cells.
8 
Cells were washed in PBS (× 3), fixed with 4% 
paraformaldehyde in PBS at room temperature for 
30 min, rinsed with PBS (× 3), and then incubated 
with 0.1 mg/mL Hoechst 33258 for 30 min at 
room temperature. Morphological evaluation of 
nuclear condensation and fragmentation was per-
formed using a fluorescent microscope (Olympus 
IX70-FL, Tokyo, Japan). The number of cells with 
apoptotic morphology was randomly assessed, 
and about 200 cells per field were counted. 
DNA fragmentation
DNA fragmentation analysis was performed by 
the method reported by Wolozin et al.
9 with 
minor modifications. Briefly, in order to extract 
DNA fragmented in the internucleosomal space, 
cells were cultured in 75 cm
2 flasks. Approximately 
(1 - 2) × 10
7 cells from each experimental condition 
were harvested. The cells were washed with PBS 
and centrifuged for 5 min. The pellets were lysed 
in 10 mmol/L Tris-HCl (pH 7.5) containing 10 
mmol/L EDTA and 0.2% Triton X-100. After cen-
trifugation at 1600 g for 5 min, the supernatants 
were incubated with 1% SDS and 5 mg/mL RNase 
A at 56℃ for 2 h and then digested with 2.5 mg/ 
mL proteinase K for at least 2 h at 37°C. After 
incubation and addition of 1 mol/L ammonium 
acetate, the DNA was precipitated with ethanol and 
dissolved in gel loading buffer. The entire sample 
was then electrophoresed on 2% agarose gels 
containing 0.1 g/mL ethidium bromide, and DNA 
fragments were visualized under ultraviolet light. 
Assessment of intracellular Ca
2+ using fura-2/ AM
[Ca
2+]i was measured microspectrofluorimetrically 
as previously described using the Ca
2+-sensitive 
indicator fura-2/AM.
10 Cells were incubated in 5 
μmol/L fura-2/AM in DMSO for 45 min at 37℃, 
rinsed twice with d-Hanks to remove the dye, and 
then trypsinized, pelleted, and resuspended in 
d-Hanks containing 0.4% bovine serum albumin 
(BSA). The fluorescence ratio (R) was assessed 
using FDSS6000 at 340 nm and 380 nm wavelengths. 
The maximal fluorescence ratio (Rmax) was deter-
mined by adding Triton X-100 (final concentration, 
0.1%), and subsequently minimal fluorescence 
ratio (Rmin) was determined by adding EGTA 
(final concentration, 5 mmol/L). The [Ca
2+]i was 
then calculated according to the equation: [Ca
2+]i= 
Kd (R-Rmin)/(Rmax-R), where Kd is the dissociation 
constant of fura-2/AM for Ca
2+ and is assumed to 
be 224 nmol/L at 37℃.
Western blot
Cultured cortical cells were scraped into ice- 
cold homogenization buffer, containing 10 mmol/ 
LTris-HCl (pH 7.4), 0.32 M sucrose, 1 mmol/L 
dithiothreitol, 1 mmol/L phenylmethylsulfonyl 
fluoride (PMSF), and 5 mmol/L EGTA, for 20 min 
at 4℃. After sonication, the cells were centrifugated 
at 4℃ (1000 g, 10 min) and the supernatants were 
used for the determination of protein concentra-
tions using the Bradford assay. Samples were 
diluted (1 : 1) in sample buffer (62.5 mmol/L Tirs- 
HCl, pH6.8, 2% SDS, 5 mmol/L β-mercaptoe-
thanol, and 10% glycerol) and boiled for 5 min. 
The Western blot analysis was carried out as 
described previously.
11 Briefly, 30 μg of protein 
from each sample were loaded onto a 12% sodium 
dodecyl sulfate-polyacrylamide gel (SDS-PAGE) 
for electrophoresis at 200 V for 30 min. Resolved 
protein samples were transferred from the gel to 
nylon membranes using an electrophoresis transfer 
apparatus, which was run at 12 V for 2 h. 
Membranes were blocked in 5% powered nonfat 
milk in Tris-buffered saline/Tween (TBST) solution 
(20 mmol/L Tris-HCl, pH 7.6, 0.1% Tween-20 in 
saline) overnight at 4℃. Membranes were then 
incubated for 1 h with a primary antibody diluted 
in blocking solution (1 : 100 for Bax, Bcl-2, and 
caspase-3). Membranes were then washed three 
times in TBST solution and incubated for 1 h with 
horseradish peroxidase-conjugated secondary 
antibody diluted in blocking solution (1 : 2000). 
Membranes were again washed three times, in-
cubated with ECL detection reagent according to 
the manufacture’s protocols, and then exposed to 
X-ray films. The amount of protein was quantified 
by densitometric analysis of the autoradiograms 
using a scanning laser densitometer. Protein levels 
of β-actin were determined to assure equal loading. ULMWH on Glutamate-Induced Apoptosis 489
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Fig. 1. Fluorescence photomicro-
graphs of cortical cells with Hoechst
33258 staining. Assayed cells were 
from four treatment groups. (A) 
Control cells; (B) Treatment with 1 
mg/L ULMWH; (C) Treatment with
100 μmol/L glutamate; (D) Treat-
ment with 100 μmol/L glutamate 
and 1 mg/L ULMWH. Examples of 
cells that would be considered apo-
ptotic by this assay are labeled with
arrows.
Statistical analysis
Statistical analyses were performed using Student 
t-test.  P < 0.05 was considered to be statistically 
significant. All data were expressed as mean ±
standard deviation (SD).
RESULTS
Effect of ULMWH on cell nuclear morphology 
and DNA fragmentation
Nuclear shape and chromosomal structure can 
be visualized using Hoechst 33258 staining 
method.
8 Cells are considered apoptotic if they 
show irregular, shrunk, and condensed nuclei 
with bright fluorescence. As seen in Fig. 1A and 
B, very few apoptotic cells were detected in the 
control (Fig. 1A) or ULMWH-treated group (Fig. 
1B), however, significantly more apoptotic cells 
were observed in the glutamate-treated group 
(Fig. 1C), which was greatly reduced by ULMWH- 
pretreatment, as demonstrated in Fig. 1D. In order 
to confirm the glutamate-induced apoptotic mor-
phology change and the effects of ULMWH 
pretreatment, DNA fragmentation study was then 
conducted on the sister cultures. As illustrated in 
Fig. 2, typically pronounced DNA ladder was 
observed in the cortical cells that were exposed to 
100 μmol/L glutamate for 24 h, which was com-
pletely blocked by ULMWH pretreatment for 24 
h and no DNA ladder was observed.
Quantification of the Hoechst 33258 stained 
apoptotic cells indicated that about 19.9% of 
control cells exhibited an apoptotic morphology, 
and there was no significant difference between 
control cells and ULMWH-treated cells. As com-
pared with control cells, the percentage of 
apoptosis in glutamate-treated cells was 33.21%. 
However, the proportion decreased in ULMWH- 
pretreated cells, which had no significant difference 
from control cells (Fig. 3), thus confirming the 
qualitative observation. 
A B
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Fig. 2. Effect of ULMWH on glutamate-induced DNA 
fragmentation (DNA ladder) in cortical cells. (A) Control 
cells; (B) Size mark; (C) Treatment with 1 mg/L ULMWH;
(D) Treatment with 100 μmol/L glutamate and 1 mg/L 
ULMWH; (E) Treatment with 100 μmol/L glutamate. 
Fig. 3. Quantitative apoptotic cortical cells evaluated by 
Hoechst 33258 staining. Multiple slides from the four 
treatment groups were viewed: Control cells (Con); 
Treatment with 1 mg/L ULMWH (U);Treatment with 100 
μmol/L glutamate (Glu); Treatment with 100 μmol/L 
glutamate and 1 mg/L ULMWH (U1). At least 200 cells 
were viewed for each count. Data were expressed as mean 
± SD (n=6). Significance was determined by Student t-test. 
*p < 0.01 vs control. 
✝p < 0.01 vs glutamate.
Fig. 4. Effect of ULMWH on glutamate-induced decrease 
in cell viability. Cell viability was measured by MTT assay.
Control cells (Con); Treatment with 100 μmol/L glutamate
(Glu); Treatment with 1 mg/L ULMWH (U); Treatment 
with 100 μmol/L glutamate and 1 mg/L ULMWH (U1). 
Data were expressed as mean ± SD (n = 6). Significance 
was determined by Student t-test. *p < 0.01 vs control. 
✝p<
0.01 vs glutamate.
Neuroprotective effect of ULMWH on cell viability
The viabilities of the treated cortical cells were 
studied using MTT assay. The optical densities 
(OD) of the cells were decreased by incubation 
with 100 μmol/L glutamate for 24 h, indicating 
that cells could be injured by excessive glutamate. 
Under this experimental condition, the decreased 
OD values could be attenuated by pretreatment 
with 1 mg/L ULMWH before glutamate incubation 
(Fig. 4).
Effect of ULMWH on Bcl-2 family proteins expres-
sion
Since Bcl-2 family proteins play critical roles in 
apoptosis induced by a wide array of death signals, 
the effects of ULMWH on glutamate-induced 
changes of levels of Bcl-2 family proteins were 
studied using Western blot (Fig. 5A). Glutamate- 
treated cells showed highly elevated-Bax protein 
level with a concomitant down-regulated Bcl-2 
content as compared with control cells. Such 
changes were reversed in the ULMWH-pretreated 
cells. There was no significant difference in the 
levels of Bax or Bcl-2 between ULMWH-treated 
cells and control cells (Fig. 5B). Errors in sample 
loading were controlled with β-actin.
Effect of ULMWH on glutamate-induced elevation 
of [Ca
2+]i 
As glutamate-mediated cell death may be 
correlated with increases of [Ca
2+]i, we examined 
[Ca
2+]i in the cells (Fig. 6). The level of [Ca
2+]i in ULMWH on Glutamate-Induced Apoptosis 491
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Fig. 5. Effect of ULMWH on Bcl-2 and Bax protein levels 
in cortical cells treated with glutamate. (A) Western blot 
of proteins isolated from cortical cells after glutamate 
treatment. Control cells (Con); Treatment with 100 μmol/L
glutamate (Glu); Treatment with 1 mg/LULMWH (U); 
Treatment with 100 μmol/L glutamate and 1 mg/L 
ULMWH (U1). (B) Quantitative analysis of ULMWH on 
the expression of Bcl-2and Bax (the relative abundance of 
the immunostaining) determined by Image Quant pro-
grammer. The levels of Bcl-2and Bax are expressed as % 
of the control. Data were expressed as mean ± SD (n = 3). 
Significance was determined by Student t-test. *p < 0.01 vs
control. 
✝p < 0.01 vs glutamate.
Fig. 6. Effect of ULMWH on the increase of [Ca
2+]i in 
cortical cells induced by 100 μmol/L glutamate applica-
tion. Control cells (Con); Treatment with 1mg/L ULMWH
(U); Treatment with 100 μmol/L glutamate (Glu); Treat-
ment with 100 μmol/L glutamate and 1 mg/L ULMWH 
(U1). The [Ca
2+]i was measured by using fura-2/AM, 
based ratiometric fluorescence assay. Data were expressed
as mean ± SD (n = 6). Significance was determined by 
Student t-test. *p <0 . 0 1  v s  c o n t r o l .  
✝p < 0.05 vs glutamate.
Fig. 7. Effect of ULMWH on Ca
2+ release induced by 
glutamate. When measuring the [Ca
2+]i, the medium con-
taining Ca
2+ was changed into Ca
2+-free medium. The [Ca
2+]i 
was measured by using fura-2/AM, based ratiometric 
fluorescence assay. Control cells (Con); 100 μmol/L gluta-
mate (Glu); Treatment with 100 μmol/L glutamate and 1
mg/L ULMWH (U1). Data were expressed as mean ± SD 
(n = 6). Significance was determined by Student t-test. *p 
< 0.05 vs control. 
✝p < 0.01 vs glutamate.
control cells was 137.68 nmol/L, whereas the 
glutamate-treated cells showed a significant rise of 
[Ca
2+]i, which was partially inhibited by pretreat-
ment with ULMWH. There was no significant 
difference between control and ULMWH-treated 
cells. 
To investigate the [Ca
2+]i-lowering pathways of 
ULMWH in cortical cells, the extracellular medium 
was changed to Ca
2+-free medium containing 1 
mmol/L EGTA (Fig. 7). However, glutamate- 
induced rise of [Ca
2+]i was still observed, and the 
increase of [Ca
2+]i was much smaller than that in 
normal culture medium. When 1 mg/L ULMWH 
was added to Ca
2+-free medium prior to the 
application of glutamate, the glutamate-induced 
rise of [Ca
2+]i was completely suppressed. Moreover, 
the magnitude of [Ca
2+]i decrease by 1 mg/L 
ULMWH in normal culture medium was almost 
equal to that in Ca
2+-free medium (normal culture 
medium: 20.76 ± 0.34 nmol/L; Ca
2+-free: 19.9 ± 
0.46 nmol/L,  p > 0.05).
A
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Fig. 8. Effcet of ULMWH on glutamate-induced caspase-3 
activation. (A) Western blot of proteins isolated from 
cortical cells after glutamate treatment. Control cells (Con);
Treatment with 100 μmol/L glutamate (Glu); Treatment 
with 1 mg/LULMWH (U); Treatment with 100 μmol/L 
glutamate and 1 mg/L ULMWH (U1). (B) Quantitative 
analysis of ULMWH on the expression of caspase-3 (the 
relative abundance of the immunostaining) determined by
Image Quant programmer. The levels of caspase-3 are ex-
pressed as % of the control. Data were expressed as 
mean ± SD (n = 6). Significance was determined by Student 
t-test. *p <0 . 0 1  v s  c o n t r o l .  
✝p < 0.01 vs glutamate.
Effect of ULMWH on caspase-3 activation
As [Ca
2+]i was elevated in glutamate-treated 
cells, its downstream protease, caspase-3, was 
assayed by Western blot analysis (Fig. 8). A 
significant 56% increase of caspase-3 protein was 
noted in glutamate-treated cells, as compared to 
that in control cells, and this increase was signi-
ficantly attenuated in ULMWH-pretreated cells. 
There was no difference between control cells and 
ULMWH-treated cells or between control cells and 
ULMWH-pretreated cells. Again, uniform sample 
loading was assured using β-actin.
DISCUSSION 
Glutamate is a major excitatory neurotransmitter 
working at a variety of excitatory synapses in the 
central nervous system. It plays important physio-
logical roles in the cellular processes underlying 
synaptic plasticity, neuronal development and ex-
citation via the activation of glutamate receptors.
12,13 
Of particular importance to all of these processes 
is the ability of the N-methyl-D-aspartate receptor 
channel to conduct Ca
2+ ions, leading to a direct 
increase of intracellular Ca
2+ through Ca
2+ channel 
from the extracellular environment. Under phy-
siological conditions, such as periods of patterned 
glutamatergic synaptic activity, the increase of 
intracellular Ca
2+ can promote synaptic stabilization 
and strengntening.
13-16 Under pathological condi-
tions, such as prolonged exposure to high con-
centrations of glutamate, excessive amounts of 
intracellular Ca
2+ are toxic, causing the so-called 
excitotoxic reaction.
17,18 H i g h  c o n c e n t r a t i o n s  o f  
glutamate have been shown to induce neuronal 
damage and late cell loss in in vitro studies using 
cultured neurons.
19,20 This is also observed in 
humans suffering from acute degenerative diseases 
such as strokes and traumatic brain injury, or 
chronic degenerative diseases including Parkinson’s 
disease, AD and multiple sclerosis.
21-23 Therefore, 
excessive glutamate accumulation in the extra-
cellular space is believed to contribute primarily 
to injury to neurons, and high concentrations of 
glutamate are often used to mimic neuronal 
excitotoxity  in vitro. 
High concentrations of glutamate have been 
shown to produce excitotoxic damage in cultured 
neurons via Ca
2+ entry throug receptor channels,
24 
and the glutamate-induced Ca
2+ overload hypothesis 
has been widely accepted as the mechanism of 
neuronal injury in glutamate-induced excitotoxi-
city.
25-27 Ca
2+ overload should elicit a series of 
neuronal injury events, including degeneration of 
DNA, important proteins and phospholipids, and 
accumulation of radical oxygen species.
28 In order 
to evaluate ULMWH modulation of changes in 
the level of intracellular Ca
2+ induced by high con-
centrations of glutamate, we first assessed the 
intracellular free Ca
2+ level in containing Ca
2+ 
medium using fura-2/AM double wavelength 
fluorometry. The results showed that the intra-
cellular Ca
2+ concentrations were significantly 
increased by glutamate, but these increases were 
partially inhibited in the ULMWH-pretreated 
cells. Secondly, we observed changes in the level 
of intracellular Ca
2+ after exposure to glutamate 
for 24 h in Ca
2+ free medium. Intracellular Ca
2+ 
A
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concentrations were also increased by glutamate, 
but these increases were completely inhibited in 
ULMWH-pretreated cells. In addition, it was very 
interesting to note that the magnitude of [Ca
2+]i 
decrease by ULMWH in medium containing Ca
2+ 
was almost equal to that in Ca
2+-free medium. 
This indicates that 24 h pretreatment of cortical 
cells with ULMWH can significantly decrease 
intracellular free Ca
2+, which may be due to inhi-
bition of the release of sequestered intracellular 
Ca
2+. Although the way by which ULMWH 
inhibited the intracellular Ca
2+ release wasn’t 
directly investigated in the present study, UFH, 
the parent drug of ULMWH, has been proved to 
be an effective competitive antagonist of inositol- 
1, 4, 5-triphosphate (IP3) receptor, not only in 
isolated membrane preparations but also in living 
cells.
29-31 Moreover, it has been observed that 
intraneuronal injection of UFH (MW 12,000) in 
vitro prevents glutamate-induced Ca
2+ release 
from intracellular stores through blocking of IP3 
receptors, thus interfering with events occurring 
in the ischemic cascade.
3 ULMWH has average 
M.W. much smaller than that of LMWH and the 
same major internal structure, α-L-IdoA-2-SO4-β (I
→4)-α-D-GIrNSO3-6-SO4, as UFH, suggesting that 
it can pass through the cell membrane and exert 
its intraneuronal effects. From these results, it can 
be inferred that ULMWH inhibited glutamate- 
induced intracellular Ca
2+ release may be attri-
butable to suppressing intracellular Ca
2+  release 
from IP3- sensitive stores. 
The elevation of the intracellular free Ca
2+ level 
also mediates the activation of Ca
2+ dependent 
enzymes,
32 including lipases, phospholipases and 
proteases, which cause neurotoxicity by catalyzing 
the release of free fatty acids such as arachidonic 
acid from membrane phospholipids. Free fatty 
acids open membrane pores, thereby facilitating 
the influx of Ca
2+ as well as releasing Ca
2+ from 
internal stores. Intracellular free Ca
2+ acts as a 
messenger to regulate growth, differentiation and 
cell death. Strong Ca
2+ influx has been reported to 
be a signal for apoptosis.
33 The crucial step of 
apoptosis is regulated by the expression of genes 
of the Bcl-2 family, which consists of both 
pro-apoptotic (e.g. Bax, Bcl-xs, Bad and Bak) and 
anti-apoptotic (e.g. Bcl-2, Bcl-xL, and mcl-1) 
molecules.
34,35 Bcl-2 and Bax are the proto-type 
oncoproteins whose functions include the 
regulation of apoptosis.
36,37 Bcl-2 protein is a 
cytosolic protein with a lipidanchoring domain, 
which allows it to target the nucleus and to inhibit 
apoptosis. Bax, a member of the Bcl-family, homo-
dimerizes and forms heterodimers with Bcl-2 
protein, thereby reducing its anti-apoptotic effect.
37,38 
Overexpression of Bax accelerates apoptotic death. 
In many cell types, Bcl-2 and Bax have been 
demonstrated to play a dominant role in the 
regulation of apoptosis.
39 For example, Bcl-2 and 
Bax are considered to play a role in regulating the 
survival and maturation of chondrocytes in joint 
cartilage.
40 In this study, we investigated the gene 
expression of the pro- and anti-apoptotic factors, 
Bax and Bcl-2, in cortical cells using immunoblot. 
The results showed that Bax: Bcl-2 ratio was 
increased by glutamate, but this increase was 
suppressed in ULMWH-pretreated cells. Bcl-2 is 
known to protect against apoptosis triggered by a 
wide range of factors.
24,41,42 However, excess Bax 
favors apoptotic cell death induced by numerous 
stimuli.
24 The data from this study strongly suggests 
that Bcl-2 family protein may be involved in the 
process of ULMWH to protect cortical cells from 
glutamate-induced apoptosis. 
Outer stimuli can initiate apoptosis through the 
above mechanism and may converge on the 
caspase pathway to execute the final phase of the 
apoptotic process.
43 The caspase family of 
proteases consists of at least 14 mammalian 
members that are constitutively expressed in 
almost all cell types as inactive proenzymes 
(zymogens) that become processed and activated 
in response to a variety of pro-apoptotic stimuli.
44 
Caspase-3 is a downstream member of the caspase 
cascade and acts as a central effector in the 
execution phase. When caspase-3 precursor 
protein CPP32 is activated by upstream signals 
such as the release of mitochondrial cytochrome 
c, triggered by Bax translocation to mitochondria,
45 
the active caspase-3 cleaves specific aspartate 
residues in proteins with various structural, 
housekeeping and regulatory functions.
46 These 
proteolytic events can lead to cell apoptosis, and 
contribute to DNA fragmentation and nuclear 
morphologic changes. Thus, substances that can 
inhibit the activity of caspase-3 may protect cells 
from apoptosis.
47,48 Since ULMWH markedly Tian-gui Yu, et al. 494
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inhibited the caspase-3 activity in the glutamate- 
treated cells, it appears to have the neuroprotective 
capacity.
The spectrum of the anti-apoptotic potential of 
UFH and LMWH in various tissues and under 
various pathological situations
49,50 is currently under 
scrutiny. In this study, our data clearly demon-
strated that ULMWH can abrogate glutamate- 
induced apoptosis in primary cultured cortical 
neurons. Pretreatment of the neurons with 
ULMWH for 24 h can prevent the rise of [Ca
2+]i 
triggered by glutamate via suppressing intracel-
lular Ca
2+ release from IP3-sensitive-internal stores, 
up-regulating the protein expression of the anti- 
apoptotic molecule Bcl-2, down-regulating the pro- 
apoptotic factor Bax, and preventing caspase-3 
activation, all of which were involved in the 
mechanism of ULMWH conferred neuroprotec-
tion and can be viewed as a stepwise path to anti- 
apoptotic effect of ULMWH. 
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